Organon & Co. (OGN) Announces American Academy of Dermatology’s Strong Recommendation for VTAMA Cream

Organon & Co. (NYSE:OGN) is one of the 13 Best Healthcare Stocks to Buy Under $10On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation in the American Academy of Dermatology’s (AAD) 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD).

Why Organon & Co. (OGN) Surged On Thursday

A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy.

Organon & Co. (NYSE:OGN) stated that the recommendation highlights the cream’s status as a steroid-free and effective option for daily disease management. It does not have precautions or label warnings, no restrictions on use duration or percentage of body surface area affected, and no contraindications.

Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.

While we acknowledge the potential of OGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.